9-PAHSA is an orally effective endogenous GPR120 agonist (EC50=18 µM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-kappaB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease[1][2][3][4].
Molecular Weight:
538.89
Purity:
99.88
CAS Number:
[1481636-31-0]
Formula:
C34H66O4
Target:
CGRP Receptor,NF-kappaB
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
